IHC - Calretinin

The tissue sample is usually obtained through a biopsy procedure, where a small piece of tissue is removed for testing.

A positive result means that calretinin is present in the tissue sample. This is commonly seen in mesothelioma, but it can also occur in other conditions.

This test is not typically used for routine screening. It is more commonly used when there is a clinical suspicion of mesothelioma, often based on symptoms, medical history, and other diagnostic findings.

The main risks are associated with the biopsy procedure, which may include bleeding, infection, and discomfort at the biopsy site.

The turnaround time for this test is usually 5 to 10 days, although this can vary depending on the laboratory.

No special preparation is required. You should continue your regular diet and medication schedule unless otherwise instructed by your healthcare provider.

Yes, the results of the IHC - Calretinin test can inform treatment decisions, including the need for further diagnostic tests, the choice of therapeutic approach, and the monitoring of disease progression.

A negative result means that calretinin was not detected in the tissue sample. This could indicate the absence of mesothelioma, but it doesn't rule out the disease entirely. Other tests may be needed to confirm the diagnosis.

While the IHC - Calretinin test can provide valuable diagnostic information, it is not typically used to monitor the course of the disease or the response to treatment.

The accuracy of the IHC - Calretinin test is quite high, but it can depend on several factors, including the quality of the sample and the technique used in the lab.

Yes, the test can be performed on individuals of any age if indicated by a healthcare provider.

The IHC - Calretinin test primarily helps in diagnosing mesothelioma, but the presence of calretinin can also be associated with other conditions. It is essential to interpret the results in the context of other clinical and diagnostic findings.

The frequency of this test is determined by your healthcare provider, based on your health condition and the need for diagnostic information.

The IHC - Calretinin test is usually part of a larger diagnostic workup, which may include other imaging studies, lab tests, and possibly additional IHC tests for other markers. Your healthcare provider will guide you based on your individual circumstances.

The IHC - Calretinin test is a type of pathology test that directly examines the presence of specific proteins in tissue cells. Other diagnostic tests may include imaging studies or molecular tests, which provide different kinds of information.

Coverage varies by individual insurance plans. It's essential to check with your insurance provider to understand what parts of the cost will be covered.

It's normal to feel anxious about medical procedures. Discuss your concerns with your healthcare provider. Understanding what to expect from the test and why it's being done can often help reduce anxiety.

Several factors can affect the accuracy of test results, including the quality of the sample, technical issues during the test, or the presence of other conditions that can mimic the expression of calretinin. Your healthcare provider will interpret the results in the context of your overall clinical picture.

If indicated, the test can be done during pregnancy. However, the decision will be made by your healthcare provider based on your specific situation.

The biopsy procedure and the IHC - Calretinin test require a controlled laboratory setting and cannot be done at home.

The IHC - Calretinin test is a reliable diagnostic tool. However, it's not 100% conclusive. It's often used in combination with other tests to confirm a diagnosis of mesothelioma.